Jonas Salk he had hoped and he found the rules imposed by the university restrictive. In 1948, Harry Weaver, the director of research at the National Foundation for Infantile Paralysis, contacted Salk. He asked Salk to find out if there were more types of polio than the three then known, offering additional space, equipment and researchers. For the first year he gathered supplies and researchers including Julius Youngner, Byron Bennett, L. James Lewis, and secretary Lorraine Friedman joined Salk's team, as well. As time went on, Salk began securing grants from the Mellon family and was able to build a working virology
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood